Dihydromitragynine (DHM).
DHM is a hydrogenated derivative of mitragynine that appears in some concentrated kratom extracts and 'next-generation' kratom-alkaloid products. Published pharmacological characterization is limited.
Chemistry
Dihydromitragynine is formed by reduction of mitragynine — specifically, hydrogenation of one or more double bonds in the parent structure. The result is a closely related but pharmacologically distinct compound. Synthetic routes have been published; the compound also appears as a minor natural component in some kratom-leaf material.
Pharmacology in brief
Limited published in vitro and animal data. Reports describe μ-opioid receptor activity at the same family pharmacophore as mitragynine and 7-OH, with differing affinity and signaling profile. We don't have enough published evidence to summarize a confident position on potency vs. mitragynine or 7-OH.
Products on the market
DHM appears in some "7-OH + DHM" combination products and as a standalone compound in a few SKUs. Volumes are lower than 7-OH or Pseudo. Filter our product library by compound "DHM" for current listings.
Open questions
- Quantitative receptor pharmacology in humans
- Tolerance and dependence relative to 7-OH and Pseudo
- Whether DHM in combination products contributes meaningfully to subjective effects vs. acts primarily as a marketing differentiator
Legal status
Not specifically scheduled at the US federal level as of mid-2026. Coverage under state kratom-alkaloid laws depends on statutory wording. See /Legal.